Nuvectis Pharma

Explore the latest insights on Nuvectis Pharma and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Nuvectis Pharma’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Medinno Pharmaceutical (Xiamen) Technology Co., Ltd. announced the completion of a Series A financing round exceeding RMB 200 million, led by Sunshine Ronghui Capital, with follow‑on investment from Xiamen Jinyuan…

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

TransThera Sciences' YOCHANRA (Tinengotinib) Receives First Prescription in China – World's First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Haisco's HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma
CompanyDrug

Haisco’s HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma